Maria Mazzocchi

Maria Mazzocchi

Auto-generated profile, based on publicly available information

Maria Mazzocchi

Oncology Department,Fondazione Poliambulanza,Brescia,Italy

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1991 in Journal of Immunological Methods
Verified
Journal Article
Closed access
AFAntonella Facchinetti
Antonella Facchinetti
LTL. Tessarollo
L. Tessarollo
MMM. Mazzocchi
M. Mazzocchi
RKR. Kingston
R. Kingston
DCD. Collavo
D. Collavo
GBG. Biasi
G. Biasi

11 August 2012 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
FAFederica Andreis
Federica Andreis
MFMarco Ferri
Marco Ferri
MMMaria Mazzocchi
Maria Mazzocchi
FMFausto Meriggi
Fausto Meriggi
ARAnna Rizzi
Anna Rizzi
AZAlberto Zaniboni
Alberto Zaniboni

29 January 2011 in Tumori Journal
Verified
Journal Article
Closed access
PDF file
FAFederica Andreis
Federica Andreis
ARAnna Rizzi
Anna Rizzi
LRLuigina Rota
Luigina Rota
FMFausto Meriggi
Fausto Meriggi
MMMaria Mazzocchi
Maria Mazzocchi
AZAlberto Zaniboni
Alberto Zaniboni
Aims and background: The aim of the study was to evaluate the attitude at our institution in using chemotherapy at the end of life in oncology patients. We compared our habits with other clinical patterns in medical oncology, calculating the temporal interval between the last chemotherapy administration and death of the patient. Patients and methods: We selected and analyzed 102 patients who received chemotherapy for metastatic or advanced solid tumors (breast, colon, gastric, pancreatic and lung cancers) and who died either in or out of a hospital or hospice from June 2007 to the end of 2009. Results: We compared 51 patients enrolled in clinical trials with 51 patients not enrolled in clinical trials. Patients of both groups died with advanced cancer between June 2007 and 2009. The following solid tumor types were represented: 48% colorectal cancer, 22% breast cancer, 30% other solid tumors (pancreatic, lung and gastric cancer). The median age at death was 62 years (range, 39 to 84), the male/female ratio was 52:50, and 69% of the patients were married. Most patients, 54%, received 2–3 lines of chemotherapy, 25% received more than 3 lines, and the remaining 21% one line only of chemotherapy. Of the 102 patients identified, 16 (16%) received chemotherapy in the last month of life, and 6 (6%) of these in the last 2 weeks. We speculated that the presence of palliative care services in the territory of residence of patients could influence the time interval between the last chemotherapy and death. We found that 52 patients (51%) lived in areas where palliative care services were not available, 27 (52%) of them received chemotherapy in the last 3 months, 8 (15%) in the last month, and 5(10%) within the last 2 weeks of life. In contrast, of the 49 patients living in the territory served by palliative care units or a hospice, none received chemotherapy during the last 2 weeks of life and 37% received it during the last 3 months of life (P = 0.003). Conclusions: Among selected patients who died for advanced cancer in our Operative Unit from 2007 to 2009, 50% received chemotherapy in the last 3 months of life. The availability of palliative care services in the territory of residence of patients can influence the interval between the last chemotherapy administration and death. Free full text available at www.tumorionline.it

15 April 2010 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
FAFederica Andreis
Federica Andreis
ARAnna Rizzi
Anna Rizzi
PMPaola Mosconi
Paola Mosconi
CBClaudia Braun
Claudia Braun
LRLuigina Rota
Luigina Rota
AZAlberto Zaniboni
Alberto Zaniboni
Background: Epidermal growth factor receptor inhibitors are widely prescribed anticancer drugs. Patients treated commonly develop dermatologic adverse drugs reactions, but rarely they are involved in systematic evaluation of their quality of life. This monocentric cross sectional study is carried out to assess quality of life in colon cancer patients experienced skin side effects due to anti epidermal growth factor receptor inhibitors therapy. Methods: Consecutive patients with skin side effects to therapy treated at Fondazione Poliambulanza were enrolled in this study. Quality of life was evaluated with the Italian validated version of Skindex-29 questionnaire, exploring three dimensions: symptoms, emotional, and physical functioning. Skindex-29 was administered one time between the eighth and the twelfth week of the treatment. Results: Forty-five consecutive patients, mainly with metastatic colon cancer (29 female, 16 male), with an average age of 59.31 years (ranging from 34-78) were included in the study and analyzed. Patients showed a great impact of skin side effects on symptoms (mean 43), followed by emotional (mean 30), and functioning (mean 26) scales. In general women, the 55-65 age class, and patients with partial remission reported the worst quality of life. Conclusions: Epidermal growth factor receptor inhibitors' skin side effects have an important impact on quality of life in advanced colon cancer patients; symptoms scale is the most effect respect to emotional and functioning scales.

26 June 2014 in Palliative and Supportive Care
Verified
Journal Article
Closed access
PDF file
FMFausto Meriggi
Fausto Meriggi
FAFederica Andreis
Federica Andreis
VPVeronica Premi
Veronica Premi
NLNadia Liborio
Nadia Liborio
CCClaudio Codignola
Claudio Codignola
AZAlberto Zaniboni
Alberto Zaniboni
Objective: Caregivers play a key role in the management of patients with cancer. However, some studies have suggested that caregivers have even more unmet needs than the patients. Method: To better identify the needs and changes in the lifestyles of the caregivers in our practice and to plan a targeted support project to decrease caregiver burden, we administered the Caregiver's QoL Index–Cancer (CQoLC) to 200 consecutive caregivers. This questionnaire assesses psychological well-being, the relationship with healthcare professionals, administration of finances, lifestyle disruption, and positive adaptation. Results: Our data showed that being a caregiver to a patient with metastatic disease negatively affected females mostly with regard to mental and emotional burden, while men complained more about their sexual life (42.3 vs. 33.6%), although this result was not significant. Some 93.5% of caregivers reported that they were pleased with their role, while 83.4% were concerned about financial difficulties. Significance of results: We strongly believe that early supportive care directed not only at patients but also to caregivers may improve the quality of life (QoL) in this population. We are currently developing a targeted support project to decrease caregiver burden.

1 December 1989 in Cellular Immunology
Verified
Journal Article
Closed access
GBGiovanni Biasi
Giovanni Biasi
MMMaria Mazzocchi
Maria Mazzocchi
PZPaola Zanovello
Paola Zanovello
DCDino Collavo
Dino Collavo
HFHilliard Festenstein
Hilliard Festenstein